Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) EBIT Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EBIT Margin for 3 consecutive years, with 2106.85% as the latest value for Q2 2025.

  • Quarterly EBIT Margin rose 15879115.0% to 2106.85% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 9721.02% through Dec 2025, up 554135.0% year-over-year, with the annual reading at 10386.54% for FY2025, 15533746.0% up from the prior year.
  • EBIT Margin for Q2 2025 was 2106.85% at Inhibrx Biosciences, down from 1595.43% in the prior quarter.
  • The five-year high for EBIT Margin was 1595.43% in Q1 2025, with the low at 160898.0% in Q2 2024.
  • Average EBIT Margin over 3 years is 49017.42%, with a median of 21956.66% recorded in 2023.
  • The sharpest move saw EBIT Margin crashed -4452476bps in 2024, then skyrocketed 15879115bps in 2025.
  • Over 3 years, EBIT Margin stood at 5403.24% in 2023, then plummeted by -824bps to 49928.0% in 2024, then surged by 96bps to 2106.85% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 2106.85%, 1595.43%, and 49928.0% for Q2 2025, Q1 2025, and Q4 2024 respectively.